Le Lézard

News by subject: Clinical Study

1 2

28 september 2022

07:15
Resverlogix Corp. ("Resverlogix" or the "Company") today announced that apabetalone's future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as...


26 september 2022

08:05
Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce it has received Health Canada clearance...


21 september 2022

17:20
Biogen Inc. today announced that The...


19 september 2022

07:30
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has completed enrollment in the Phase IIa clinical trial of...

07:00
Psyence Group Inc.  ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial...


16 september 2022

07:00
Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003),...


15 september 2022

08:00
Novan, Inc. ("the Company" or "Novan") , today announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase 3 pivotal...


14 september 2022

06:00
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has filed an amended protocol to the U.S....


13 september 2022

08:00
Acasti Pharma Inc. ("Acasti" or the "Company") , today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102,...

07:00
Rubius Therapeutics, Inc. , a biopharmaceutical company that...


8 september 2022

10:30
Healthcare professionals, social workers and counsellors working in the substance use field are experiencing higher levels of burnout. A new study released today by the Canadian Centre on Substance Use and Addiction (CCSA) says the drug toxicity...

07:00
Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the ADVANCE-2 trial of AXS-05, an...


7 september 2022

08:05
The completion of the ISA's review of the Collector Test Environmental Impact Statement (EIS) paves the way for TMC subsidiary, Nauru Ocean Resources Inc (NORI), to conduct its planned pilot collection system trials on its NORI-D exploration area in...

07:00
Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of a post-hoc analysis comparing the effects of Sunosi®...

07:00
KETARXtm Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARXtm Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better align with intramuscular and intravenous...


1 september 2022

07:00
Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") a clinical stage Canadian pharmaceutical development company, is pleased to report positive results from the full data set of its Phase 2a Study evaluating NP-120 ("Ifenprodil") for the...

07:00
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is pleased to announce acceptance of a study abstract for presentation at...

07:00
Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the EMERGE trial of AXS-07 for the...


31 august 2022

08:30
In time for the return to school, a national poll conducted by the Canadian Women's Foundation reveals the top challenges parents and caregivers believe their children aged nine to 19 have faced over the past two years: Low self-esteem and lack of...

08:00
UniDoc Health Corp. (FRA: L7T) ("UniDoc," or the "Company"), an innovator in the telehealth sector, is pleased to announce it has successfully concluded a series of pilot trials with OnPharm-United, a network of independent pharmacies in Canada....


23 august 2022

07:00
Tilray Brands, Inc. ("Tilray" or the "Company") , a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis...


16 august 2022

10:30
Vena Medical, a leading developer of cutting-edge neurovascular devices, announces the successful treatment of the first five patients in the world using the Vena BDACtm at London Health Sciences Centre (LHSC) University Hospital and The Ottawa...


15 august 2022

07:50
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received approval from the U.K. Medicines and Healthcare...


3 august 2022

07:50
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of July 19, 2022 it has been granted patent no. 3104072 by the...


28 july 2022

08:00
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Altheia Science, a gene therapy company pioneering cell and gene therapy strategies to treat...

07:30
Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary endpointBiogen is also evaluating litifilimab in...


27 july 2022

08:00
Acasti Pharma Inc. ("Acasti" or the "Company") , today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug bupivacaine in 48 healthy...

08:00
LexaGene Holdings, Inc.,  ("LexaGene" or the "Company"), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, provides a brief summary of preliminary data...


21 july 2022

07:30
Field Trip Health Ltd. ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today the first successful dosings in the Phase 1 Clinical Study entitled "A Double-Blind, Randomized,...


20 july 2022

16:10
Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that while its partner, Assembly...

08:00
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market...


15 july 2022

17:05
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, has today published its financial results for the quarter ended May 31, 2022. A full...


12 july 2022

08:45
Cannabix Technologies Inc. (the "Company or Cannabix") developer of marijuana breathalyzer devices for law enforcement and the workplace reports that the Company is participating in a new comprehensive multi-analysis study of subjects under the...


7 july 2022

07:00
Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") , a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its planned Phase 1 clinical human study of AP-188 ("N,N-dimethyltryptamine" or "DMT")....


6 july 2022

07:15
Zenith Epigenetics Ltd. ("Zenith" or the "Company") announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI sponsored clinical trials for safety and efficacy in multiple oncology indications with significant unmet...


5 july 2022

08:00
C-POLARtm Technologies Inc., a bioprotection company dedicated to setting the new standard of health and safety through the protection against viruses and microorganisms, today announced positive results from independent studies of C-POLARtm's...


29 june 2022

08:00
Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the...


25 june 2022

04:05
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients...


24 june 2022

11:45
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company's U.S. Food & Drug...


21 june 2022

07:15
Zenith Epigenetics Ltd. ("Zenith" or the "Company") announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) clinical trial combining ZEN-3694 + Pfizer Inc.'s Talzenna (talazoparib) was highlighted at an oral...

07:00
Xenon...


17 june 2022

07:30
Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and...

07:00
Mydecine Innovations Group (NEO: MYCO) ("Mydecine" or the "Company"), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared MYCO-001...


16 june 2022

07:30
Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and...


9 june 2022

14:00
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) included a more diverse...

03:05
Reliq Health Technologies Inc. ("Reliq" or the "Company"), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed five...


7 june 2022

07:00
PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a leader in specialty...


6 june 2022

20:15
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...

13:55
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company's U.S. Food & Drug...


3 june 2022

08:00
Biogen Inc.  and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), a biosimilar candidate referencing ACTEMRA®/ROACTEMRA® (tocilizumab), anti-interleukin-6 receptor monoclonal antibody, at the Annual...

1 2